Clinical Trials Browser

Astrocytoma × vorasidenib × Clear all

Astrocytoma, Oligodendroglioma

NCT06809322 2026-02-17

VIGOR

Phase 3 Recruiting

468 enrolled

CNS

Astrocytoma

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Phase 3 Not yet recruiting

408 enrolled

CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Approved for marketing

CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Clinical Trials

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

VIGOR

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Vorasidenib Expanded Access Program